DE69914611D1 - Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen - Google Patents

Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen

Info

Publication number
DE69914611D1
DE69914611D1 DE69914611T DE69914611T DE69914611D1 DE 69914611 D1 DE69914611 D1 DE 69914611D1 DE 69914611 T DE69914611 T DE 69914611T DE 69914611 T DE69914611 T DE 69914611T DE 69914611 D1 DE69914611 D1 DE 69914611D1
Authority
DE
Germany
Prior art keywords
chains
conjugates
proteins
exact length
producing polyamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69914611T
Other languages
English (en)
Other versions
DE69914611T2 (de
Inventor
Keith Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gryphon Therapeutics Inc
Original Assignee
Gryphon Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Sciences filed Critical Gryphon Sciences
Application granted granted Critical
Publication of DE69914611D1 publication Critical patent/DE69914611D1/de
Publication of DE69914611T2 publication Critical patent/DE69914611T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/04—Preparatory processes
    • C08G69/06—Solid state polycondensation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polyamides (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
DE69914611T 1998-08-28 1999-08-23 Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen Expired - Fee Related DE69914611T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9835198P 1998-08-28 1998-08-28
US98351P 1998-08-28
US10526198P 1998-10-22 1998-10-22
US105261P 1998-10-22
US12426699P 1999-03-11 1999-03-11
US124266P 1999-03-11
PCT/US1999/019280 WO2000012587A2 (en) 1998-08-28 1999-08-23 Polyamide chains of precise length, methods to manufacture them and their conjugates

Publications (2)

Publication Number Publication Date
DE69914611D1 true DE69914611D1 (de) 2004-03-11
DE69914611T2 DE69914611T2 (de) 2004-12-23

Family

ID=27378582

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69914611T Expired - Fee Related DE69914611T2 (de) 1998-08-28 1999-08-23 Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
DE69936322T Expired - Fee Related DE69936322T2 (de) 1998-08-28 1999-08-23 Polyamideketten von genauer Länge und deren Konjugate mit Proteinen
DE1107998T Pending DE1107998T1 (de) 1998-08-28 1999-08-24 Polyamidketten von genauer länge, verfahren zu deren herstellung und deren konjugate mit proteinen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69936322T Expired - Fee Related DE69936322T2 (de) 1998-08-28 1999-08-23 Polyamideketten von genauer Länge und deren Konjugate mit Proteinen
DE1107998T Pending DE1107998T1 (de) 1998-08-28 1999-08-24 Polyamidketten von genauer länge, verfahren zu deren herstellung und deren konjugate mit proteinen

Country Status (13)

Country Link
US (2) US6552167B1 (de)
EP (1) EP1107998B1 (de)
JP (1) JP2002528562A (de)
KR (1) KR20010085742A (de)
CN (1) CN1330675A (de)
AT (2) ATE364654T1 (de)
AU (1) AU764144B2 (de)
CA (1) CA2351739A1 (de)
DE (3) DE69914611T2 (de)
DK (1) DK1400551T3 (de)
ES (1) ES2170042T3 (de)
HK (1) HK1043801A1 (de)
WO (1) WO2000012587A2 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1107998B1 (de) * 1998-08-28 2004-02-04 Gryphon Sciences Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
DE19924606A1 (de) * 1999-05-28 2000-11-30 Graffinity Pharm Design Gmbh Ligand-Anker-Konjugate
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
MXPA03001449A (es) * 2000-09-01 2004-12-13 Gryphon Therapeutics Inc Compuestos generadores de tioester estables a nucleofilos, metodos para su produccion y su uso.
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
CN1454097A (zh) * 2000-09-08 2003-11-05 格莱风治疗公司 聚合物修饰的合成的蛋白质类
JP4387669B2 (ja) 2000-10-13 2009-12-16 ザイジェン エス．アー． 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US20040138412A1 (en) * 2001-09-07 2004-07-15 Paolo Botti Extended native chemical ligation
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
WO2004060925A2 (en) * 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Multiplex polymer ligation
ES2323465T3 (es) * 2003-05-12 2009-07-16 Affymax, Inc. Peptidos novedosos que se unen al receptor de la eritropoyetina.
MXPA05012314A (es) 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
WO2004101600A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
ES2395413T3 (es) 2003-05-12 2013-02-12 Affymax, Inc. Péptidos que se unen al receptor de eritropoyetina
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
EP1771573A4 (de) * 2004-07-21 2009-02-18 Ambrx Inc Nichtnatürliche kodierte aminosäuren verwendende biosynthetische polypeptide
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP1836298B1 (de) 2004-12-22 2012-01-18 Ambrx, Inc. Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
JP5410020B2 (ja) 2005-02-02 2014-02-05 ノヴォ ノルディスク アー／エス インスリン誘導体
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
ATE529442T1 (de) 2005-06-03 2011-11-15 Ambrx Inc Verbesserte humane interferon-moleküle und ihre verwendungen
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
PT2339014E (pt) 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
US20090082254A1 (en) * 2006-02-14 2009-03-26 Novo Nordisk A/S Coupling of Polypeptides at the C-Terminus
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
US8501693B2 (en) * 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
WO2008030613A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
DK2615108T3 (en) * 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
WO2008030614A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
WO2008067729A1 (en) * 2006-12-06 2008-06-12 Nankai University The poltpeptides and the synthetic method of the same
EP2101821B1 (de) 2006-12-15 2014-08-13 Baxter International Inc. Faktor-viia-(poly)sialsäurekonjugat mit verlängerter in-vivo-halbwertszeit
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
AU2008326324B9 (en) 2007-11-20 2012-11-15 Ambrx, Inc. Modified insulin polypeptides and their uses
EP3103880A1 (de) 2008-02-08 2016-12-14 Ambrx, Inc. Modifizierte leptinpolypeptide und deren verwendungen
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
MX348657B (es) 2008-09-26 2017-06-21 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
EP3216800A1 (de) 2008-09-26 2017-09-13 Ambrx, Inc. Modifizierte tierische erythropoietin-polypeptide und deren verwendungen
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
EP2459224B1 (de) 2009-07-27 2016-06-01 Baxalta GmbH Koagulationsproteinkonjugate
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
NZ600363A (en) 2009-12-21 2014-07-25 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
NZ612320A (en) 2010-12-22 2015-06-26 Baxter Healthcare Sa Materials and methods for conjugating a water soluble fatty acid derivative to a protein
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
EP3505534A1 (de) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
BR112015004022B1 (pt) 2012-08-31 2023-04-25 Sutro Biopharma, Inc Aminoácidos modificados compreendendo um grupo azido
WO2014068463A2 (en) * 2012-11-03 2014-05-08 Mahesh Kandula Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
WO2018136779A2 (en) 2017-01-19 2018-07-26 The University Of Chicago OXALOBACTER FORMIGENES(Of)-DERIVED FACTORS FOR THE TREATMENT OF TREATMENT/PREVENTION OF EXCESS OXALATE LEVELS
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
WO2020018799A1 (en) 2018-07-18 2020-01-23 The University Of Chicago Compositions comprising sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith
US20220056093A1 (en) 2018-09-11 2022-02-24 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
EP3867265A1 (de) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen
BR112021015832A2 (pt) 2019-02-12 2022-01-18 Ambrx Inc Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
JP2023538071A (ja) 2020-08-20 2023-09-06 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE343210B (de) 1967-12-20 1972-03-06 Pharmacia Ab
US4028315A (en) * 1970-10-16 1977-06-07 E. R. Squibb & Sons, Inc. Solid phase synthesis of peptides
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2360794C2 (de) 1973-12-06 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung von Peptiden
US4028313A (en) * 1975-06-25 1977-06-07 Bayer Aktiengesellschaft Process for the production of water-dispersible polyhydroxyl compounds
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
GB1578348A (en) 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4192798A (en) * 1978-11-20 1980-03-11 Bioresearch, Inc. Rapid, large scale, automatable high pressure peptide synthesis
JPS5792435A (en) 1980-11-28 1982-06-09 Matsushita Electric Ind Co Ltd Formation of magnetic tape
US4415665A (en) 1980-12-12 1983-11-15 Pharmacia Fine Chemicals Ab Method of covalently binding biologically active organic substances to polymeric substances
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
IL74177A (en) 1984-02-03 1989-09-10 Abbott Lab Stabilized enzyme conjugate composition containing a calcium salt and a polyethylene glycol
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
IT1190389B (it) * 1985-09-19 1988-02-16 Eniricerche Spa Esapeptidi ad attivita' ipotensiva
US4802512A (en) 1986-02-25 1989-02-07 Kabushiki, Kaisha, Kodera, Denshi, Seisakusho Automatic wire decorticating and cutting method and apparatus
US4745180A (en) 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5097070A (en) * 1989-11-03 1992-03-17 Texaco Chemical Company High molecular weight trifunctional polyoxyethylene amines
DE69322266T2 (de) 1992-04-03 1999-06-02 Perkin Elmer Corp Proben zusammensetzung und verfahren
IL107715A0 (en) 1992-11-25 1994-02-27 Baxter Int Water soluble non-immunogenic polyamide cross-linking agents
FR2698628B1 (fr) * 1992-12-02 1995-02-17 Fournier Ind & Sante Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CA2156924A1 (en) * 1993-12-27 1995-07-06 Ton That Hai Water soluble non-immunogenic polyamide cross-linking agents
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP0856026A1 (de) 1995-10-19 1998-08-05 Receptagen Corporation Polyethylenglycolen mit diskreter länge
EP1107998B1 (de) * 1998-08-28 2004-02-04 Gryphon Sciences Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen

Also Published As

Publication number Publication date
JP2002528562A (ja) 2002-09-03
HK1043801A1 (zh) 2002-09-27
DE69936322D1 (de) 2007-07-26
WO2000012587A3 (en) 2000-06-02
DE1107998T1 (de) 2002-10-17
CA2351739A1 (en) 2000-03-09
US20030228274A1 (en) 2003-12-11
WO2000012587A8 (en) 2001-09-20
DE69914611T2 (de) 2004-12-23
ES2170042T3 (es) 2004-10-01
ES2170042T1 (es) 2002-08-01
AU764144B2 (en) 2003-08-14
KR20010085742A (ko) 2001-09-07
EP1107998B1 (de) 2004-02-04
DE69936322T2 (de) 2008-02-21
ATE364654T1 (de) 2007-07-15
AU5688399A (en) 2000-03-21
US6552167B1 (en) 2003-04-22
WO2000012587A2 (en) 2000-03-09
EP1107998A2 (de) 2001-06-20
CN1330675A (zh) 2002-01-09
DK1400551T3 (da) 2007-10-15
ATE258946T1 (de) 2004-02-15

Similar Documents

Publication Publication Date Title
DE69914611D1 (de) Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
DE69831402D1 (de) Nicht antigen wirkende verzweigte polymerkonjugate
CA2174325A1 (en) Non-antigenic branched polymer conjugates
ATE279912T1 (de) Verfahren zur zelltransfektion mit liposomal- verkapselten nukleinsäuren
NO975729D0 (no) Forbindelser og peptider som binder til etytropoietinreseptoren
PT1144459E (pt) Acidos hialuronicos reticulados e as suas utilizacoes em medicina
DK113790D0 (da) Vandig gel paa basis af hyaluronsyre og desoxyribonucleinsyre anvendelig i kosmetik og fremgangsmaade til fremstilling deraf
ES2155819T3 (es) Inmunoglobulinas hibridas.
DE69028412D1 (de) Verfahren zum transport von molekülen in eukaryotenzellen
DE3675887D1 (de) Elektronisch leitfaehige stickstoffpolymere, verfahren zur herstellung derselben, elektrochronische anzeigezelle, und diese polymere verwendender elektrochemischer generator.
WO2001041812A3 (en) Amphiphilic polymers and polypeptide conjugates comprising same
SE8804164A0 (sv) Farmaceutisk beredning
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1
ATE201559T1 (de) Pflanzenbehandlungsmittel
ES549185A0 (es) Procedimiento para sintetizar peptidos a partir de aminoaci-dos
DE69806164T2 (de) Verfahren zur herstellung von polyanilin mit hohem molekulargewicht in seiner emeraldinform
ATE212360T1 (de) Polyethylenglycol-hirudin-konjugate, deren verfahren zur herstellung und verwendung für die heilung von thrombosen
ATE481641T1 (de) Verfahren zur fixierung eines proteins auf einem pyrrolpolymerisat, und dessen verwendung zur herstellung eines sensors
DK0977859T3 (da) Den neurotrofiske faktor NNT-1
DE59701734D1 (de) Unlösliche, nur wenig quellbare polymerisate mit modifizierten aminogruppen, verfahren zu ihrer herstellung und ihre verwendung
ATE248807T1 (de) Verfahren zur herstellung von n-hydrocarbyl- substituierten amiden
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
ES2123311T3 (es) Compuestos tetrakisazoicos, su preparacion y empleo como colorantes.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GRYPHON THERAPEUTICS, INC., SOUTH SAN FRANCISCO, C

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee